Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

23.60 +0.60 (+2.61%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,639,967
Open	22.84
Bid (Size)	23.25 (100)
Ask (Size)	23.85 (1,000)
Prev. Close	23.00
Today's Range	22.50 - 24.00
52wk Range	18.41 - 46.50
Shares Outstanding	70,814,462
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

The Great Rebalancing: Thin Holiday Trading and Institutional Pivots Cap a Volatile 2025

January 01, 2026

As the clock struck midnight to usher in 2026, investors were left reflecting on a final week of 2025 that was anything but festive. While the broader year was a triumph for equity markets—with the S&P...

Via MarketMinute

Performance

YTD	N/A	N/A
1 Month	-35.4%	-35.4%
3 Month	-21.8%	-21.8%
6 Month	-40.4%	-40.4%
1 Year	-43.1%	-43.1%

More News

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

December 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today ↗

December 30, 2025

Via The Motley Fool

Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss ↗

December 30, 2025

Via Stocktwits

Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today ↗

December 29, 2025

Via The Motley Fool

Which stocks are experiencing notable movement on Monday? ↗

December 29, 2025

Via Chartmill

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

Via MarketMinute

Keep an eye on the top gainers and losers in Monday's session. ↗

December 29, 2025

Via Chartmill

Why Did RARE Stock Plunge Over 41% Today? ↗

December 29, 2025

Via Stocktwits

Traders are paying attention to the gapping stocks in Monday's session. ↗

December 29, 2025

Via Chartmill

Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta

December 29, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Participate in Investor Conferences in December

November 24, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update

November 04, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

November 04, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Announces First Patient Dosed in Aurora Study Evaluating GTX-102 in Additional Angelman Syndrome Genotypes and Age Groups

October 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update

October 28, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 24, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

September 30, 2025

From Ultragenyx Pharmaceutical Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Ultragenyx Pharmaceutical Inc. - Common Stock publicly traded?

Yes, Ultragenyx Pharmaceutical Inc. - Common Stock is publicly traded.

What exchange does Ultragenyx Pharmaceutical Inc. - Common Stock trade on?

Ultragenyx Pharmaceutical Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock?

The ticker symbol for Ultragenyx Pharmaceutical Inc. - Common Stock is RARE on the Nasdaq Stock Market

What is the current price of Ultragenyx Pharmaceutical Inc. - Common Stock?

The current price of Ultragenyx Pharmaceutical Inc. - Common Stock is 23.60

When was Ultragenyx Pharmaceutical Inc. - Common Stock last traded?

The last trade of Ultragenyx Pharmaceutical Inc. - Common Stock was at 01/02/26 04:00 PM ET

What is the market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock?

The market capitalization of Ultragenyx Pharmaceutical Inc. - Common Stock is 1.67B

How many shares of Ultragenyx Pharmaceutical Inc. - Common Stock are outstanding?

Ultragenyx Pharmaceutical Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.